The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease.
Saved in:
| Title: | The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease. |
|---|---|
| Authors: | Rao JS; IGC Pharma Inc., Potomac, MD, United States., Alejandra Tangarife M; IGC Pharma Inc., Potomac, MD, United States., Venegas MM; IGC Pharma Inc., Potomac, MD, United States., Forero B; IGC Pharma Inc., Potomac, MD, United States., González Tamayo LL; IGC Pharma Inc., Potomac, MD, United States., Escobar-Gallego JP; IGC Pharma Inc., Potomac, MD, United States., Rodríguez-Soacha DA; IGC Pharma Inc., Potomac, MD, United States., Ferreiros A; IGC Pharma Inc., Potomac, MD, United States., Mukunda R; IGC Pharma Inc., Potomac, MD, United States. |
| Source: | Frontiers in psychiatry [Front Psychiatry] 2026 Jan 13; Vol. 16, pp. 1709266. Date of Electronic Publication: 2026 Jan 13 (Print Publication: 2025). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101545006 Publication Model: eCollection Cited Medium: Print ISSN: 1664-0640 (Print) Linking ISSN: 16640640 NLM ISO Abbreviation: Front Psychiatry Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-0640 |
|---|---|
| DOI: | 10.3389/fpsyt.2025.1709266 |
